| 李龙,冷婧,徐春红,等.结直肠癌肿瘤组织微管相关蛋白轻链 3、三级淋巴结构与程序性死亡因子 /程序性死亡配体 1相关性及临床意义[J].安徽医药,2026,30(7):1403-1407. |
| 结直肠癌肿瘤组织微管相关蛋白轻链 3、三级淋巴结构与程序性死亡因子 /程序性死亡配体 1相关性及临床意义 |
| Correlation and clinical significance of microtubule-associated protein light chain 3, tertiary lymph structure and programmed death factor/programmed death ligand 1 in colorectal cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2026.07.026 |
| 中文关键词: 结直肠肿瘤 微管相关蛋白轻链 3 三级淋巴结构 程序性死亡因子 /程序性死亡配体 1 相关性 临床意义 |
| 英文关键词: Colorectal neoplasms Microtubule associated protein light chain 3 Tertiary lymphoid structure Programmed death factor/programmed death ligand 1 Relevance Clinical significance |
| 基金项目: |
|
| 摘要点击次数: 215 |
| 全文下载次数: 117 |
| 中文摘要: |
| 目的探讨结直肠癌肿瘤组织微管相关蛋白轻链 3(LC3)、三级淋巴结构( TLS)与程序性死亡因子( PD-1)/程序性死亡配体 1(PD-L1)相关性及临床意义。方法回顾性收集 2021年 3月至 2024年 2月中国人民解放军海军第九七一医院收治的 113例结直肠癌病人石蜡标本及临床资料，检测肿瘤组织 LC3、TLS、PD-1、PD-L1表达，应用 Spearman相关性分析检验肿瘤组织 TLS表达与 LC3及 PD-1、PD-L1的关系， Pearson相关性分析检验 LC3表达与 PD-1、PD-L1关系，比较不同临床特征病人肿瘤组织 LC3、TLS表达。结果癌组织 LC3表达阳性率 66.37%(75/113)、表达量 0.86±0.25高于癌旁组织 26.55%(30/113)、 0.47±0.15(P<0.001)；肿瘤组织 TLS+病人占比 64.60%(73/113)高于 TLS. 35.40%(40/113)(P<0.001)；癌组织 PD-1、PD-L1表达高于癌旁组织( P<0.05)113例研究对象， 94例( 83.19%)表现出癌组织 PD-1、PD-L1水平高于癌旁组织，仅有 19例( 16.81%)表现为癌组织 PD-1、PD-L1水，平低于癌旁组织； TLS+病人 LC3表达量高于 TLS.病人( P<0.05)； Spearman相关性分析显示，结直肠癌肿瘤组织 LC3表达量与 TLS呈正相关( r=0.76，P<0.05)TLS与 PD-1、PD-L1呈正相关( r=0.71、0.80，P<0.001)； Pearson相关性分析显示，结 |
| 英文摘要: |
| Objective To explore the correlation and clinical significance of microtubule-associated protein light chain 3 (LC3), ter-tiary lymphoid structure (TLS) and programmed death factor (PD-1)/programmed death ligand 1 (PD-L1) in colorectal cancer. Meth. ods Paraffin specimens and clinical data of 113 patients with colorectal cancer treated in No.971 Hospital of the People's LiberationArmy Navy from March 2021 to February 2024 were retrospectively collected to detect the expression of LC3, TLS, PD-1 and PD-L1 in tumor tissues, and Spearman correlation was used to analyze the relationship between the expression of TLS and LC3, PD-1 and PD-L1 in tumor tissues. The relationship between LC3 expression and PD-1 and PD-L1 was analyzed by Pearson correlation, and the expres-sion levels of LC3 and TLS in tumor tissues were compared among patients with different clinical characteristics.Results The positiverate of LC3 expression in tumor tissues and the expression level of LCe were higher than those in adjacent normal tissues [66.37% (75/113) vs. 26.55% (30/113), (0.86±0.25) vs. (0.47±0.15); P<0.001]. The proportion of patients with TLS+ in tumor tissues was higher than that with TLS. [64.60% (73/113) vs. 35.40% (40/113), P<0.001]. The expression levels of PD-1 and PD-L1 in tumor tissues were higher than those in adjacent normal tissues (P<0.05). Among 113 subjects, 94 (83.19%) cases showed higher levels of PD-1 and PD-L1 in tu-mor tissues than in adjacent normal tissues, while only 19 (16.81%) cases showed lower levels of PD-1 and PD-L1 in tumor tissues than in adjacent normal tissues. LC3 expression in TLS+ patients was higher than that in TLS. patients (P< 0.05). Spearman correlation anal-ysis results showed that LC3 expression in colorectal cancer tissues was positively correlated with TLS (r=0.76, P<0.05), and TLS was positively correlated with PD-1 and PD-L1 (r=0.71, 0.80, P<0.001). Pearson correlation analysis results showed that LC3 expression incolorectal cancer tumor tissues was positively correlated with PD-1 and PD-L1 (r=0.75, 0.60, P<0.001). The LC3 positive rate and TLS+ rate of tumor tissues in patients with tumor diameter ≥5 cm were higher than those in patients with tumor diameter < 5 cm (P< 0.05). The LC3 positive rate and TLS+ rate of tumor tissues in T3 stage patients were higher than those in T1 and T2 stage patients (P<0.05). The positive rates of LC3 and TLS+ in tumor tissues of patients with lymph node metastasis were higher than those without lymph node metastasis (P< 0.05).Conclusion LC3 expression in colorectal cancer tumor tissues may contribute to the formation of TLS. Both LC3and TLS are positively correlated with PD-1/PD-L1, which not only has the potential to screen patients who may benefit from future anti-PD-1/PD-L1 immunotherapy, but also provides a new approach for enhancing anti-tumor immunity. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
